Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 12.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 242,007 shares of the life sciences company’s stock after buying an additional 27,190 shares during the period. Stephens Investment Management Group LLC owned about 0.15% of Illumina worth $32,339,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc boosted its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $32,000. TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the period. Private Trust Co. NA grew its stake in Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in Illumina in the third quarter worth $63,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Stephens boosted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Barclays dropped their price target on shares of Illumina from $145.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Monday, February 3rd. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. Finally, Morgan Stanley cut their target price on Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Nine research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $161.40.

Illumina Stock Performance

NASDAQ ILMN opened at $111.06 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business’s fifty day moving average is $136.70 and its two-hundred day moving average is $135.29. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, analysts forecast that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.